These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36258237)

  • 1. Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag:  a case report.
    Lattanzio M; Ferrari M; Martini S; Ceriani F; Imporzani A; Marino F; De Ponti R; Cosentino M
    J Med Case Rep; 2022 Oct; 16(1):385. PubMed ID: 36258237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
    Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
    Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
    PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study.
    Lau E; Kotlyar E; Makanji Y; Yu DY; Tan JY; Casorso J; Kouhkamari MH; Lim S; Wu DB; Bloomfield P
    J Med Econ; 2024; 27(1):596-604. PubMed ID: 38488130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
    Angus JA; Soeding PF; Hughes RJA; Wright CE
    Eur J Pharmacol; 2017 Jun; 804():111-116. PubMed ID: 28300593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
    Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
    Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension.
    Wu S; Hoang HB; Yang JZ; Papamatheakis DG; Poch DS; Alotaibi M; Lombardi S; Rodriguez C; Kim NH; Fernandes TM
    Chest; 2022 Dec; 162(6):1360-1372. PubMed ID: 35841932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV; Aleevskaya AM
    Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data.
    Dong S; Guo X; Wang H; Sun C
    Ther Adv Respir Dis; 2024; 18():17534666231223606. PubMed ID: 38179676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
    Aypar E; Alehan D; Karagöz T; Aykan H; Ertugrul İ
    Cardiol Young; 2020 May; 30(5):681-685. PubMed ID: 32290885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evidence base for specific pulmonary vasodilators in adults with congenital heart disease].
    Shmalts AA; Gorbachevsky SV
    Ter Arkh; 2021 Sep; 93(9):1106-1116. PubMed ID: 36286872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
    Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
    Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report.
    Alexandre A; Furtado I; Carvalho L; Gonçalves F; Melo A; Alves J; Santos M; Reis A
    ESC Heart Fail; 2023 Aug; 10(4):2722-2727. PubMed ID: 37336527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study.
    Omura J; Makanji Y; Tanabe N; Yu DY; Tan JY; Lim S; Kouhkamari MH; Casorso J; Wu DB; Bloomfield P
    Pulm Ther; 2023 Dec; 9(4):511-526. PubMed ID: 37991630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
    Iglarz M; Bossu A; Wanner D; Bortolamiol C; Rey M; Hess P; Clozel M
    Life Sci; 2014 Nov; 118(2):333-9. PubMed ID: 24582812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
    van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC
    Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.